Home > Insider Trading > Filing (0001181431-13-049008)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1113148	Infinity Pharmaceuticals Inc.	INFI	Pharmaceutical Preparations (2834)	330655706

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1375124	Q Adelene Perkins	C/O Infinity Pharmaceuticals, Inc. 780 Memorial Drive Cambridge MA 02139	Pres & Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-09-12	31,924	$20.81	460,611	No	4	S	Direct
Common Stock	Disposition	2013-09-13	13,076	$20.50	447,535	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,882	Indirect	By 401k

Footnotes

The dispositions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2013.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.61 to $20.99, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.60, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.